Harvard Bioscience (HBIO) Net Income towards Common Stockholders (2010 - 2026)

Harvard Bioscience (HBIO) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$3.4 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 93.19% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was -$9.8 million, a 83.08% increase from a year earlier, with the FY2025 full-year figure at -$56.7 million, down 368.79% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$3.4 million, down from -$2.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for HBIO reached as high as $2.4 million in Q2 2022 and fell as low as -$50.3 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$4.9 million across 5 years, with a median of -$2.3 million in 2025.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 663.66% in 2022 and fell as far as 1902.94% in 2022.
• Year by year, Net Income towards Common Stockholders stood at -$1.7 million in 2022, then surged by 72.03% to -$466000.0 in 2023, then jumped by 177.25% to $360000.0 in 2024, then tumbled by 882.78% to -$2.8 million in 2025, then slipped by 21.5% to -$3.4 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$3.4 million in Q1 2026, -$2.8 million in Q4 2025, and -$1.2 million in Q3 2025.